A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Official Title

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Summary:

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

Trial Description

Primary Outcome:

  • Compare the efficacy of IMO-2125 in combination with ipilimumab versus ipilimumab alone
  • Compare the efficacy of IMO-2125 in combination with ipilimumab versus ipilimumab alone
A Phase 3 global, multi-centre, open-label comparison of ipilimumab with and without intratumoural IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society